GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » COGS-to-Revenue

Qiagen NV (Qiagen NV) COGS-to-Revenue : 0.38 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Qiagen NV COGS-to-Revenue?

Qiagen NV's Cost of Goods Sold for the three months ended in Dec. 2023 was $193 Mil. Its Revenue for the three months ended in Dec. 2023 was $509 Mil.

Qiagen NV's COGS to Revenue for the three months ended in Dec. 2023 was 0.38.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Qiagen NV's Gross Margin % for the three months ended in Dec. 2023 was 62.08%.


Qiagen NV COGS-to-Revenue Historical Data

The historical data trend for Qiagen NV's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV COGS-to-Revenue Chart

Qiagen NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.34 0.36 0.35 0.37

Qiagen NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.37 0.37 0.37 0.38

Qiagen NV COGS-to-Revenue Calculation

Qiagen NV's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=731.623 / 1965.311
=0.37

Qiagen NV's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=193.062 / 509.162
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qiagen NV  (NYSE:QGEN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Qiagen NV's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 193.062 / 509.162
=62.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Qiagen NV COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Qiagen NV's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen NV (Qiagen NV) Business Description

Address
Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Executives
Prof. Dr. Elaine R. Mardis Supervisory Board
Roland Sackers Board of Directors
Thierry Bernard Board of Directors
Lawrence A. Rosen Supervisory Board